BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2679683)

  • 1. A multicenter international study on the activity of sulbactam/ampicillin, ampicillin, and cefoxitin against anaerobic bacteria and introduction of a new model of susceptibility testing in mixed infections.
    Heizmann WR; Heilmann F; Werner H
    Suppl Int J Gynecol Obstet; 1989; 2():7-12; discussion 47-8. PubMed ID: 2679683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin.
    Heizmann W; Heilmann F; Werner H
    Infection; 1987; 15(5):370-4. PubMed ID: 3692611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of a combination of ampicillin and sulbactam against clinical anaerobic isolates].
    Werner H; Heizmann W; Heilmann F
    Arzneimittelforschung; 1988 Jul; 38(7):866-8. PubMed ID: 3207432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre study to evaluate the effect of sulbactam/ampicillin combination on anaerobic micro-organisms.
    Leone F; Morandotti MG; Mazzella P; Sanna A; Ravizzola G; Colombrita D; Pinzi G; Turano R; Menozzi MG; Lecchini R
    J Int Med Res; 1990; 18(3):191-200. PubMed ID: 2193834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP; Sidorenko SV; Budanov SV
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children.
    Citron DM; Goldstein EJ; Kenner MA; Burnham LB; Inderlied CB
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S356-60. PubMed ID: 7548597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of resistance to anaerobic organisms in Australia.
    Munro R
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):159S-163S. PubMed ID: 2591175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriology of 100 consecutive diabetic foot infections and in vitro susceptibility to ampicillin/sulbactam versus cefoxitin.
    Borrero E; Rossini M
    Angiology; 1992 Apr; 43(4):357-61. PubMed ID: 1558322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of ampicillin/sulbactam against cefoxitin-resistant anaerobic bacteria.
    Jones RN; Barry AL
    J Antimicrob Chemother; 1988 Jan; 21(1):135-8. PubMed ID: 3356620
    [No Abstract]   [Full Text] [Related]  

  • 11. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.
    Heizmann WR; Heilmann F; Egeler B; Werner H
    Infection; 1990; 18(2):117-21. PubMed ID: 2332245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ampicillin plus sulbactam in vitro activity against anaerobes.
    Heilmann F; Heizmann W; Werner H
    Drugs; 1988; 35 Suppl 7():84-8. PubMed ID: 3220012
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic interchange of ampicillin-sulbactam for cefoxitin.
    Lawrenz CA; Cole P; Theodorou A; Cook RL; Bermann L
    Am J Hosp Pharm; 1991 Oct; 48(10):2150-4. PubMed ID: 1781470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.
    Jones RN
    Diagn Microbiol Infect Dis; 1990; 13(4):353-5. PubMed ID: 2076598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of the sulbactam-ampicillin combination.
    Sessarego FV; Botta GA; Pesce A; Schito GC
    J Chemother; 1989 Dec; 1(6):384-7. PubMed ID: 2614505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Mar; 32(3):403-6. PubMed ID: 3364960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.